http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1572211-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30beaaa993ebfd38cfa2df185ff97bb6 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
filingDate | 2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4ebce5a2d7ef0ef4dd289d6ac01bcc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ddbc0af5e0437414bbeb5a2e353750f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b256c13f221509f446b53cfbc29750b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_873d246795683c098d9382c3c08017c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188a1decd3f7f788dde2ed9614d1e70e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeab4061ac9e2da8709ca56182b95cdb |
publicationDate | 2005-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1572211-A1 |
titleOfInvention | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines |
abstract | The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; "a" is a single bond; "b", "c", "d", "e" and "f" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; "a" and "d" are each double bonds; "b", "c", "e" and "f" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke. |
priorityDate | 2002-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 704.